Alexza begins phase 2a trial of AZ-004 in schizophrenic agitation

By Lisa Kerner

Charlotte, N.C., Sept. 22 - Alexza Pharmaceuticals, Inc. started a phase 2a clinical trial with AZ-004 (Staccato loxapine), an inhalation product being developed for the acute treatment of agitation in schizophrenic patients.

In the multi-center, randomized, double-blind proof-of-concept study, 120 patients will receive either two doses of AZ-004 or a placebo.

The Palo Alto, Calif., pharmaceutical company will use the change in the Panss Excited Component scale as the primary efficacy measure.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.